Please assess the completion status of the following clinical trial:

Trial Title: Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological documentation of adenocarcinoma of the colon or rectum~* Progression during or within 3 months following the last administration of approved standard therapies. Patients treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy~* Patients with measurable or non measurable disease~* Eastern Cooperative Oncology Group (ECOG) Performance Status of \</= 1~* Life expectancy of at least 3 months~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Unstable/uncontrolled cardiac disease~* History of arterial or venous thrombotic or embolic events~* Symptomatic metastatic brain or meningeal tumors~* Patients with evidence or history of bleeding diathesis~* Interstitial lung disease - Persistent proteinuria \>/= grade 3~* Unresolved toxicity \> grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity \</= Grade 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib (Stivarga, BAY73-4506)+BSC (Type: EXPERIMENTAL): Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
- Placebo+BSC (Type: PLACEBO_COMPARATOR): Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).

Based on this trial design, predict the completion outcome and termination type (if applicable).